Literature DB >> 18806813

Identification of alpha 1L-adrenoceptor in mice and its abolition by alpha 1A-adrenoceptor gene knockout.

I Muramatsu1, S Morishima, F Suzuki, H Yoshiki, A S M Anisuzzaman, T Tanaka, M C Rodrigo, B E Myagmar, P C Simpson.   

Abstract

BACKGROUND AND
PURPOSE: The alpha(1L)-adrenoceptor has pharmacological properties that distinguish it from three classical alpha(1)-adrenoceptors (alpha(1A), alpha(1B) and alpha(1D)). The purpose of this was to identify alpha(1L)-adrenoceptors in mice and to examine their relationship to classical alpha(1)-adrenoceptors. EXPERIMENTAL APPROACH: Radioligand binding and functional bioassay experiments were performed on the cerebral cortex, vas deferens and prostate of wild-type (WT) and alpha(1A)-, alpha(1B)- and alpha(1D)-adrenoceptor gene knockout (AKO, BKO and DKO) mice. KEY
RESULTS: The radioligand [(3)H]-silodosin bound to intact segments of the cerebral cortex, vas deferens and prostate of WT, BKO and DKO but not of AKO mice. The binding sites were composed of two components with high and low affinities for prazosin or RS-17053, indicating the pharmacological profiles of alpha(1A)-adrenoceptors and alpha(1L)-adrenoceptors. In membrane preparations of WT mouse cortex, however, [(3)H]-silodosin bound to a single population of prazosin high-affinity sites, suggesting the presence of alpha(1A)-adrenoceptors alone. In contrast, [(3)H]-prazosin bound to two components having alpha(1A)-adrenoceptor and alpha(1B)-adrenoceptor profiles in intact segments of WT and DKO mouse cortices, but AKO mice lacked alpha(1A)-adrenoceptor profiles and BKO mice lacked alpha(1B)-adrenoceptor profiles. Noradrenaline produced contractions through alpha(1L)-adrenoceptors with low affinity for prazosin in the vas deferens and prostate of WT, BKO and DKO mice. However, the contractions were abolished or markedly attenuated in AKO mice. CONCLUSIONS AND IMPLICATIONS: alpha(1L)-Adrenoceptors were identified as binding and functional entities in WT, BKO and DKO mice but not in AKO mice, suggesting that the alpha(1L)-adrenoceptor is one phenotype derived from the alpha(1A)-adrenoceptor gene.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18806813      PMCID: PMC2607200          DOI: 10.1038/bjp.2008.360

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  46 in total

1.  Cloning of rabbit alpha(1b)-adrenoceptor and pharmacological comparison of alpha(1a)-, alpha(1b)- and alpha(1d)-adrenoceptors in rabbit.

Authors:  H Piao; T Taniguchi; S Nakamura; J Zhu; F Suzuki; D Mikami; I Muramatsu
Journal:  Eur J Pharmacol       Date:  2000-05-12       Impact factor: 4.432

2.  Distribution of alpha-1 adrenoceptor subtypes in RNA and protein in rabbit eyes.

Authors:  Fumiko Suzuki; Takanobu Taniguchi; Seigo Nakamura; Yoshio Akagi; Chikara Kubota; Makoto Satoh; Ikunobu Muramatsu
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

Review 3.  Alpha 1-adrenergic receptor regulation: basic science and clinical implications.

Authors:  G A Michelotti; D T Price; D A Schwinn
Journal:  Pharmacol Ther       Date:  2000-12       Impact factor: 12.310

Review 4.  International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors.

Authors:  David R Poyner; Patrick M Sexton; Ian Marshall; David M Smith; Remi Quirion; Walter Born; Roman Muff; Jan A Fischer; Steven M Foord
Journal:  Pharmacol Rev       Date:  2002-06       Impact factor: 25.468

5.  The alpha(1D)-adrenergic receptor directly regulates arterial blood pressure via vasoconstriction.

Authors:  Akito Tanoue; Yoshihisa Nasa; Takaaki Koshimizu; Hitomi Shinoura; Sayuri Oshikawa; Takayuki Kawai; Sachie Sunada; Satoshi Takeo; Gozoh Tsujimoto
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

6.  beta1-adrenergic receptors mediate beta3-adrenergic-independent effects of CGP 12177 in brown adipose tissue.

Authors:  A A Konkar; Y Zhai; J G Granneman
Journal:  Mol Pharmacol       Date:  2000-02       Impact factor: 4.436

7.  Abolition of (-)-CGP 12177-evoked cardiostimulation in double beta1/beta2-adrenoceptor knockout mice. Obligatory role of beta1-adrenoceptors for putative beta4-adrenoceptor pharmacology.

Authors:  A J Kaumann; S Engelhardt; L Hein; P Molenaar; M Lohse
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2001-01       Impact factor: 3.000

8.  An alpha(1A)/alpha(1L)-adrenoceptor mediates contraction of canine subcutaneous resistance arteries.

Authors:  S A Argyle; J C McGrath
Journal:  J Pharmacol Exp Ther       Date:  2000-11       Impact factor: 4.030

9.  Contractile actions of imidazoline alpha-adrenoceptor agonists and effects of noncompetitive alpha1-adrenoceptor antagonists in human vas deferens.

Authors:  Nnaemeka Amobi; John Guillebaud; Amir Kaisary; R W Lloyd-Davies; Eileen Turner; I Christopher H Smith
Journal:  Eur J Pharmacol       Date:  2003-02-21       Impact factor: 4.432

10.  Knockout of the alpha 1A/C-adrenergic receptor subtype: the alpha 1A/C is expressed in resistance arteries and is required to maintain arterial blood pressure.

Authors:  D Gregg Rokosh; Paul C Simpson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-01       Impact factor: 11.205

View more
  15 in total

1.  Agonist pharmacology at recombinant α1A - and α1L -adrenoceptors and in lower urinary tract α1 -adrenoceptors.

Authors:  Hatsumi Yoshiki; Junsuke Uwada; Hidenori Umada; Tadashi Kobayashi; Toshihiro Takahashi; Tomio Yamakawa; Akio Yamaguchi; Osamu Yokoyama; Ikunobu Muramatsu
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

2.  What makes the α(1A)-adrenoceptor gene express the α(1L)-adrenoceptor functional phenotype?

Authors:  Sabatino Ventura
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

3.  Alpha1A/B-knockout mice explain the native alpha1D-adrenoceptor's role in vasoconstriction and show that its location is independent of the other alpha1-subtypes.

Authors:  L Methven; P C Simpson; J C McGrath
Journal:  Br J Pharmacol       Date:  2009-12       Impact factor: 8.739

Review 4.  What makes the α1A -adrenoceptor gene product assume an α1L -adrenoceptor phenotype?

Authors:  Carl W White; Edilson Dantas da Silva Junior; Linzi Lim; Sabatino Ventura
Journal:  Br J Pharmacol       Date:  2019-03-27       Impact factor: 8.739

5.  Pharmacologically distinct phenotypes of α1B -adrenoceptors: variation in binding and functional affinities for antagonists.

Authors:  Hatsumi Yoshiki; Junsuke Uwada; Abu Syed Md Anisuzzaman; Hidenori Umada; Ryoji Hayashi; Mie Kainoh; Takayoshi Masuoka; Matomo Nishio; Ikunobu Muramatsu
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

Review 6.  Phenotype pharmacology of lower urinary tract α(1)-adrenoceptors.

Authors:  A Nishimune; H Yoshiki; J Uwada; A S M Anisuzzaman; H Umada; I Muramatsu
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 7.  Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH).

Authors:  S Ventura; V l Oliver; C W White; J H Xie; J M Haynes; B Exintaris
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

8.  Isolation and pharmacological characterization of AdTx1, a natural peptide displaying specific insurmountable antagonism of the alpha1A-adrenoceptor.

Authors:  L Quinton; E Girard; A Maiga; M Rekik; P Lluel; G Masuyer; M Larregola; C Marquer; J Ciolek; T Magnin; R Wagner; J Molgó; R Thai; C Fruchart-Gaillard; G Mourier; J Chamot-Rooke; A Ménez; S Palea; D Servent; N Gilles
Journal:  Br J Pharmacol       Date:  2009-12-15       Impact factor: 8.739

9.  The alpha 1B/D-adrenoceptor knockout mouse permits isolation of the vascular alpha 1A-adrenoceptor and elucidates its relationship to the other subtypes.

Authors:  L Methven; M McBride; G A Wallace; J C McGrath
Journal:  Br J Pharmacol       Date:  2009-06-30       Impact factor: 8.739

10.  Effects of ρ-Da1a a peptidic α(1) (A) -adrenoceptor antagonist in human isolated prostatic adenoma and anaesthetized rats.

Authors:  S Palea; A Maiga; V Guilloteau; M Rekik; M Guérard; C Rouget; P Rischmann; H Botto; P Camparo; P Lluel; N Gilles
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.